Fu Jianing, Zuber Julien, Shonts Brittany, Obradovic Aleksandar, Wang Zicheng, Frangaj Kristjana, Meng Wenzhao, Rosenfeld Aaron M, Waffarn Elizabeth E, Liou Peter, Lau Sai-Ping, Savage Thomas M, Yang Suxiao, Rogers Kortney, Danzl Nichole M, Ravella Shilpa, Satwani Prakash, Iuga Alina, Ho Siu-Hong, Griesemer Adam, Shen Yufeng, Prak Eline T Luning, Martinez Mercedes, Kato Tomoaki, Sykes Megan
Columbia Center for Translational Immunology, Department of Medicine and.
Center for Computational Biology and Bioinformatics, Department of Systems Biology, Columbia University, New York, New York, USA.
J Clin Invest. 2021 Apr 15;131(8). doi: 10.1172/JCI141698.
In humans receiving intestinal transplantation (ITx), long-term multilineage blood chimerism often develops. Donor T cell macrochimerism (≥4%) frequently occurs without graft-versus-host disease (GVHD) and is associated with reduced rejection. Here we demonstrate that patients with macrochimerism had high graft-versus-host (GvH) to host-versus-graft (HvG) T cell clonal ratios in their allografts. These GvH clones entered the circulation, where their peak levels were associated with declines in HvG clones early after transplant, suggesting that GvH reactions may contribute to chimerism and control HvG responses without causing GVHD. Consistently, donor-derived T cells, including GvH clones, and CD34+ hematopoietic stem and progenitor cells (HSPCs) were simultaneously detected in the recipients' BM more than 100 days after transplant. Individual GvH clones appeared in ileal mucosa or PBMCs before detection in recipient BM, consistent with an intestinal mucosal origin, where donor GvH-reactive T cells expanded early upon entry of recipient APCs into the graft. These results, combined with cytotoxic single-cell transcriptional profiles of donor T cells in recipient BM, suggest that tissue-resident GvH-reactive donor T cells migrated into the recipient circulation and BM, where they destroyed recipient hematopoietic cells through cytolytic effector functions and promoted engraftment of graft-derived HSPCs that maintain chimerism. These mechanisms suggest an approach to achieving intestinal allograft tolerance.
在接受肠道移植(ITx)的人类患者中,长期多谱系血液嵌合体常常会形成。供体T细胞大嵌合体(≥4%)频繁出现,且无移植物抗宿主病(GVHD),并与排斥反应减少相关。在此,我们证明大嵌合体患者的同种异体移植物中具有高的移植物抗宿主(GvH)与宿主抗移植物(HvG)T细胞克隆比率。这些GvH克隆进入循环系统,其峰值水平与移植后早期HvG克隆数量的下降相关,这表明GvH反应可能有助于嵌合体的形成并控制HvG反应,而不引发GVHD。一致的是,在移植后100多天,在受体的骨髓中同时检测到了包括GvH克隆在内的供体来源的T细胞以及CD34+造血干细胞和祖细胞(HSPCs)。单个GvH克隆在受体骨髓中被检测到之前,先出现在回肠黏膜或外周血单核细胞中,这与肠道黏膜起源一致,即供体GvH反应性T细胞在受体抗原呈递细胞进入移植物时早期就开始扩增。这些结果,结合受体骨髓中供体T细胞的细胞毒性单细胞转录谱,表明组织驻留的GvH反应性供体T细胞迁移到受体循环系统和骨髓中,在那里它们通过细胞溶解效应功能破坏受体造血细胞,并促进维持嵌合体的移植物来源的HSPCs的植入。这些机制提示了一种实现肠道同种异体移植耐受的方法。